Nuclear estrogen receptor β in lung/cancer: Expression and survival differences by sex

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7280-7287

  Schwartz, Ann G ^a,b   Prysak, Geoffrey M ^a   Murphy, Valerie ^a   Lonardo, Fulvio ^b   Pass, Harvey ^b   Schwartz, Jan ^a,b   Brooks, Sam ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PARAFFIN;

ADULT; ARTICLE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; CELL NUCLEUS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 27144527294     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0498     Document Type: Article

References (50)

1. Miller BA, Kolonel LN, Bernstein L, et al., editors. Racial, ethnic patterns of cancer in the United States 1988-1992. Bethesda (MD): National Cancer Institute; 1996. NIH Publication No. 96-4104.
2. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996;88:183-92.
3. Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993;138:281-93.
4. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994;54:5801-3.
5. Mollerup S, Ryberg D, Hewer A, Phillips DH, Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999;59:3317-20.
6. Kure EH, Ryberg D, Hewer A, et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996;17:2201-5.
7. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994;86:869-70.
8. Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res 1988;48:7279-84.
9. Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989;44:833-9.
10. Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer 1987;40:604-9.
11. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004;10:113-23.
12. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005;65:1598-605.
13. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997;82:4258-65.
14. Canver CC, Memoli VA, Vanderveer PL, Dingivan CA, Mentzer RM, Jr. Sex hormone receptors in non-small-cell lung cancer in human beings. J Thorac Cardiovasc Surg 1994;108:153-7.
15. Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg 2002;8:69-73.
16. Omoto Y, Kobayashi Y, Nishida K, et al. Expression, function, and clinical implications of the estrogen receptor β in human lung cancers. Biochem Biophys Res Commun 2001;285:340-7.
17. Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors α and β in human lung tissue and cell lines. Lung Cancer 2002;37:153-9.
18. Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of α and β estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002;188:125-40.
19. Stabile LP, Davis AL, Gubish CT, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen. Cancer Res 2002;62:2141-50.
20. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30.
21. Travis WD, Brambilla E, Mueller-Hermelink K, Harris C: International Academy of Pathology, International Association for the Study of Lung Cancer. Tumours of the lung, pleura and heart. In: WHO classification of tumours. Pathology and genetics. Lyon (France): IARC; 2004.
22. Cox DR. Regression models and life-tables. J R Stat Soc [Ser B] 1972;34:187-202.
23. Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg 2002;73:403-5; discussion 406.
24. Su JM, Hsu HK, Chang H, et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res 1996;16:3803-6.
25. Ollayos CW, Riordan GP, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med 1994;118:630-2.
26. Di Nunno L, Larsson LG, Rinehart JJ, Beissner RS. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med 2000;124:1467-70.
27. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 1996;67:357-64.
28. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2001. Bethesda (MD): National Cancer Institute; 2004.
29. Omoto Y, Inoue S, Ogawa S, et al. Clinical value of the wild-type estrogen receptor β expression in breast cancer. Cancer Lett 2001;163:207-12.
30. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004;10:7490-9.
31. Mann S, Laucirica R, Carlson N, et al. Estrogen receptor β expression in invasive breast cancer. Hum Pathol 2001;32:113-8.
32. O'Neill PA, Davies MP, Shaaban AM, et al. Wild-type oestrogen receptor β (ERβ1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers. Br J Cancer 2004;91:1694-702.
33. Davies MP, O'Neill PA, Innes H, et al. Correlation of mRNA for oestrogen receptor β splice variants ERβ1, ERβ2/ERβcx and ERβ5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol 2004;33:773-82.
34. Palmieri C, Lam EW, Mansi J, et al. The expression of ERβcx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 2004;10:2421-8.
35. Moore KA, Mery CM, Jaklitsch MT, et al. Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg 2003;76:1789-95.
36. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000;74:311-7.
37. Umayahara Y, Kawamori R, Watada H, et al. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994;269:16433-42.
38. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997;277:1508-10.
39. Hall JM, McDonnell DP. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-78.
40. Pettersson K, Gustafsson JA. Role of estrogen receptor β in estrogen action. Annu Rev Physiol 2001;63:165-92.
41. Siegfried JM. Women and lung cancer: does oestrogen play a role? Lancet Oncol 2001;2:506-13.
42. Martel C, Melner MH, Gagne D, Simard J, Labrie F. Widespread tissue distribution of steroid sulfatase, 3 β-hydroxysteroid dehydrogenase/δ 5-δ 4 isomerase (3 β-HSD), 17 β-HSD 5 α-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 1994;104:103-11.
43. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-82.
44. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
45. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002;21:4000-8.
46. Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and non-genomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 2004;286:L694-700.
47. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005;65:1459-70.
48. Stabile LP, Siegfried JM. Estrogen receptor pathways in lung cancer. Curr Oncol Rep 2004;6:259-67.
49. Patrone C, Cassel TN, Pettersson K, et al. Regulation of postnatal lung development and homeostasis by estrogen receptor β. Mol Cell Biol 2003;23:8542-52.
50. Casson PR, Elkind-Hirsch KE, Buster JE, Hornsby PJ, Carson SA, Snabes MC. Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol 1997;90:995-8.